Biotech Startups

Rosalind Dx is a diagnostics company developing and commercializing medical tests, with team experience that includes launching a prenatal test.

1 investor

Rose Pharma is a pharmaceutical company developing therapies in gastroenterology and metabolic disorders. Led by experienced executives from major pharmaceutical firms, the company operates in the medtech/biotech sectors.

1 investor

Rosebud Biosciences develops therapies for rare genetic diseases in children by creating organoid models that replicate patient genetic mutations and using drug screening to identify potential cures. The company uses human-derived organoids combined with robotics and machine learning to accelerate drug discovery across cardiac, hepatic, neural, and kidney disease targets.

1 investor

Rosetta Omics is a deeptech healthcare startup combining spatial multiomics profiling and AI to advance precision medicine in oncology. It develops technology for cancer diagnostics and clinical research, supported by a team of scientists, clinicians, and oncology experts.

1 investor

Route 92 Medical develops medical devices and procedural solutions for patients undergoing neurovascular intervention. The company was founded by physicians and collaborates with leading clinicians to address key challenges in neurointerventional surgery.

1 investor

Royalty Pharma acquires and manages pharmaceutical royalties from approved drugs and therapies, providing investors exposure to the biopharma sector without early-stage development risk. The company operates as a market leader in the pharmaceutical royalty market with a diversified portfolio of long-duration revenue streams.

1 investor

RS Research develops polymer-drug conjugates for targeted chemotherapy and theranostics in oncology, aiming to improve the therapeutic index in cancer treatment. The company's platform technology addresses the efficacy-toxicity trade-off challenge in targeted therapies.

1 investor

The Royal Society of Chemistry is a professional membership organisation that connects the global chemistry community through partnerships, conferences, networks and publications. It sets standards for chemical scientists, promotes open access to scientific knowledge, and advocates for chemistry's role in addressing societal challenges including healthcare, environmental protection, and clean energy.

1 investor

Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets. The company focuses on therapeutic development for patients with limited treatment options.

1 investor

Ruminant Biotech develops a rumen bolus that releases bromoform to reduce methane emissions from cattle by approximately 70%, supporting low-carbon livestock farming. The product targets dairy and beef producers seeking to lower greenhouse gas emissions while maintaining pasture-based grazing systems.

1 investor

RyboDyn develops breakthrough immunotherapies by identifying and targeting previously hidden disease markers through its proprietary RyboCypher™ technology platform. The company serves patients in need of next-generation treatments for diseases associated with cryptic biological targets.

1 investor

S2Media is a certified woman-owned manufacturer of laboratory microbiological culture media, including custom and specialty media for research, clinical, and educational labs across North America. Its FDA-registered facility produces cGMP-compliant products aligned with standards such as USP, EPA, AOAC, and CLSI.

1 investor

SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates. The company has advanced its lead candidate SAB-142 for Type 1 Diabetes into Phase 2b clinical trials.

1 investor

SACRA Therapeutics is a drug discovery company developing therapeutics that target the RNA epitranscriptome, with a focus on oncology. It combines expertise in drug discovery, clinical oncology, and epitranscriptomics to pursue a novel therapeutic approach for patients.

1 investor

Safi Biotherapeutics manufactures adult stem-cell derived human red blood cells (mRBCs) as a cell therapy blood transfusion product, aiming to produce them at industrial scale for civilian and military transfusion needs. Its work targets both chronic transfusion indications, such as sickle cell disease, and acute settings including hospitals and battlefields.

1 investor

SageMedic is a California-licensed clinical laboratory providing cancer treatment testing and diagnostics through its SAGE Oncotest™ platform. The company serves oncologists and cancer patients seeking more effective preoperative care approaches.

1 investor

SAGES develops bio-based dyes derived from phytochemical extractions that replace synthetic dyes in textile and materials applications, achieving industry-standard performance while reducing carbon emissions and eliminating toxic chemical pollution. The company targets fashion brands, manufacturers, and designers seeking sustainable colouration solutions.

1 investor

Sahlgrenska Science Park is an accelerator and innovation hub that supports life science and health technology companies, located at the Sahlgrenska medical campus in Gothenburg, Sweden. It facilitates collaboration between researchers, clinicians, entrepreneurs, and industry partners to develop and scale healthcare innovations.

1 investor

SAI Med is a healthcare company that aims to improve global healthcare through insights and data-driven solutions. The company operates with experienced leadership teams serving industry and community healthcare needs.

1 investor

PSS Solutions is an independent consulting and advisory group focused on intellectual property, helping organizations improve and manage their IP operations. It combines expertise, strategic advice, and technology to support change management and operational performance.

1 investor

SampleFacts develops microsampling devices for simplified blood cell and plasma collection, targeting researchers, clinical study professionals, and healthcare providers. The company builds on university research to enable easier, faster, and more reliable blood sampling for research, clinical studies, and diagnostics.

1 investor

Biopharmaceutical company developing first-in-class therapeutics for rare genetic and neurodegenerative diseases with a focus on autophagy enhancement.

1 investor

Sanavia discovers novel cancer-specific epitopes using proprietary immunization technology and AI to enable more effective antibody therapies for oncology. The company develops epitope discovery platforms and antibody drug candidates targeting multiple cancer types to expand treatment options for patients.

1 investor

Sancilio & Company provides guidance and regulatory support to early-stage biopharmaceutical entrepreneurs on compliance, manufacturing, and funding strategy. Through its subsidiary Clearway Global, the firm offers a network of FDA-regulated services including drug manufacturing, formulation development, clinical trials, and regulatory submissions.

1 investor